درحال بروزرسانی برخی قسمت های سایت هستیم! از شکیبایی شما سپاسگذاریم
Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene-edited engineered CAR T-cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 17 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life science-focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq global market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS).